Oncogene Cancer Research

Two prospective phase II trials at #ESMOBC26 just settled something the field has been debating retrospectively. #SATEEN (LBA4): #saci+ #trastuzumab after prior T-DXd in HER2+ MBC. ORR 3.7%. One response in 27 patients. Median PFS 2.3 months. Stopped for futility. #HER3_DXd: ORR 39% in ADC-naive HR+/HER2- disease. Prior TOPO1 ADC exposure wiped that out across every subtype. Different antibody targets. Same collapse. Because resistance here is payload-driven, not antigen-driven. SN-38 and DXd are different molecules but the same mechanism. Abelman et al. (Clin Cancer Res 2025) showed acquired TOP1 mutations in 12.9% of patients at ADC progression median duration on the second TOPO1 ADC: 52 days versus 455 on the first. >>Post-ADC trial design has to start from the payload up, not the target down. #ESMOBC26 #BCsm

After discontinuing the NVL-655 trial due to liver toxicity, ALK-positive patient and ALK Positive board member, Jeff Sturm, accessed the investigational drug zidesamtinib through a single-patient IND. Read his experience here: alkpositive.org/blog/patient-p… #LearnAboutALKPositive

@jillfeldman4-to know her is to love her! 🩵Jill is a #lungcancer patient, advocate, colleague, + friend to the entire #cancerresearch community. Huge congrats on receiving @AACR ‘26 Distinguished Patient Advocacy + Engagement Award. @LUNGevity @lcrf_org @GO2forLungCancr #AACR26